Scott Haden Kollins
Adjunct Professor in the Department of Psychiatry and Behavioral Sciences
Overview
Scott H. Kollins, PhD received his undergraduate degree in psychology from Duke and his Master’s and Doctorate degrees in Clinical Psychology from Auburn University. After completing his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Dr. Kollins has published more than 125 scientific papers in peer-reviewed journals. Over the past 10 years, his research has been supported by 6 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, and EPA, and he currently holds a mid-career K24 award from NIDA. He has also served as PI on more than 40 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology. He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is an Associate Editor for the Journal of Attention Disorders and has reviewed for more than 50 different peer-reviewed journals. He is an elected member of the College on Problems of Drug Dependence and the American College of Neuropsychopharmacology. Dr. Kollins is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. His research interests are in the areas of psychopharmacology and the intersection of ADHD and substance abuse, particularly cigarette smoking.
Selected Grants
Paternal Transgenerational Epigenetic Legacy from Use of Cannabis awarded by John Templeton Foundation (Co-Project Leader). 2017 to 2021
Increasing Motivation in ADHD Via Self-activation of VTA awarded by National Institutes of Health (Co-Principal Investigator). 2016 to 2021
Smoking/Nicotine Dependence in Attention Deficit Hyperactivity Disorder (ADHD) awarded by National Institutes of Health (Principal Investigator). 2017 to 2020
Modeling the Neurobehavioral Basis of Extrinsic and Volitional Motivation in ADHD awarded by National Institutes of Health (Co-Sponsor). 2017 to 2020
Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers awarded by National Institutes of Health (Co Investigator). 2016 to 2020
A randomized, sham-controlled, crossover study to evaluate the effects of noise cancelling headphones on neurocognitive and academic outcomes in children and adolescents diagnosed with ADHD awarded by Bose Corporation (Principal Investigator). 2017 to 2019
Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers awarded by National Institutes of Health (Principal Investigator). 2015 to 2019
A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Laboratory Classroom Study with KP415 in Children with Attention-Deficit/Hyperactivity Disorder awarded by KemPharm, Inc (Principal Investigator). 2017 to 2019
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-deficit/Hyperactivity Disorder awarded by Shire Pharmaceutical Development US Inc. (Principal Investigator). 2015 to 2019
mSMART: Mobile App based Personalized Solutions and Tools for Medication Adherence of Rx Pills awarded by Intelligent Automation Inc. (Co Investigator). 2014 to 2019
Pages
García-Marín, Luis M., et al. “Large-scale genetic investigation reveals genetic liability to multiple complex traits influencing a higher risk of ADHD.” Sci Rep, vol. 11, no. 1, Nov. 2021, p. 22628. Pubmed, doi:10.1038/s41598-021-01517-7. Full Text
Weiss, Margaret D., et al. “Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.” J Child Adolesc Psychopharmacol, vol. 31, no. 9, Nov. 2021, pp. 610–22. Pubmed, doi:10.1089/cap.2021.0034. Full Text
Kollins, Scott H., et al. “A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.” J Child Adolesc Psychopharmacol, vol. 31, no. 9, Nov. 2021, pp. 597–609. Pubmed, doi:10.1089/cap.2021.0077. Full Text
Engelhard, Matthew, et al. “Patterns of Health Services Use Before Age 1 in Children Later Diagnosed With ADHD.” J Atten Disord, vol. 25, no. 12, Oct. 2021, p. 1639. Pubmed, doi:10.1177/1087054720914352. Full Text
Weissler, E. Hope, et al. “Correction to: The role of machine learning in clinical research: transforming the future of evidence generation.” Trials, vol. 22, no. 1, Sept. 2021, p. 593. Pubmed, doi:10.1186/s13063-021-05571-4. Full Text
Perochon, Sam, et al. “A scalable computational approach to assessing response to name in toddlers with autism.” J Child Psychol Psychiatry, vol. 62, no. 9, Sept. 2021, pp. 1120–31. Pubmed, doi:10.1111/jcpp.13381. Full Text
Faraone, Stephen V., et al. “The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder.” Neurosci Biobehav Rev, vol. 128, Sept. 2021, pp. 789–818. Pubmed, doi:10.1016/j.neubiorev.2021.01.022. Full Text
Sweitzer, Maggie M., et al. “Reactions to reduced nicotine content cigarettes in a sample of young adult, low-frequency smokers.” Psychopharmacology (Berl), vol. 238, no. 9, Sept. 2021, pp. 2429–38. Pubmed, doi:10.1007/s00213-021-05864-1. Full Text
Weissler, E. Hope, et al. “The role of machine learning in clinical research: transforming the future of evidence generation.” Trials, vol. 22, no. 1, Aug. 2021, p. 537. Pubmed, doi:10.1186/s13063-021-05489-x. Full Text
Chang, Zhuoqing, et al. “Computational Methods to Measure Patterns of Gaze in Toddlers With Autism Spectrum Disorder.” Jama Pediatr, vol. 175, no. 8, Aug. 2021, pp. 827–36. Pubmed, doi:10.1001/jamapediatrics.2021.0530. Full Text
Pages
Childress, Ann Catherine, et al. “2.22 Lisdexamfetamine Dimesylate for Preschool Children With ADHD.” Journal of the American Academy of Child &Amp; Adolescent Psychiatry, vol. 57, no. 10, Elsevier BV, 2018, pp. S165–66. Crossref, doi:10.1016/j.jaac.2018.09.110. Full Text
Kollins, Scott H., et al. “2.40 A Multicenter, Randomized, Active-Control Registration Trial of Software Treatment for Actively Reducing Severity of ADHD (Stars-Adhd) to Assess the Efficacy and Safety of a Novel, Home-Based, Digital Treatment for Pediatric ADHD.” Journal of the American Academy of Child &Amp; Adolescent Psychiatry, vol. 57, no. 10, Elsevier BV, 2018, pp. S172–S172. Crossref, doi:10.1016/j.jaac.2018.09.128. Full Text
Lunsford-Avery, J. R., et al. “0762 Sleeping at Home: Feasibility and Tolerability of Ambulatory Polysomnography for Use with Adolescents with Attention-Deficit/Hyperactivity Disorder.” Sleep, vol. 41, no. suppl_1, Oxford University Press (OUP), 2018, pp. A283–84. Crossref, doi:10.1093/sleep/zsy061.761. Full Text
Kollins, Scott, et al. “Delta-9-Tetrahydrocannabinol Exposure Alters Sperm Methylation Profiles: Concurrent Results From Humans and Rats.” Neuropsychopharmacology, vol. 42, NATURE PUBLISHING GROUP, 2017, pp. S642–43.
Mitchell, John T., et al. “21.2 Substance Use Among Children With and Without Attention-Deficit/Hyperactivity Disorder Followed Prospectively Into Early Adulthood in the MTA.” Journal of the American Academy of Child &Amp; Adolescent Psychiatry, vol. 56, no. 10, Elsevier BV, 2017, pp. S334–35. Crossref, doi:10.1016/j.jaac.2017.07.700. Full Text
Murphy, S. K., et al. “Environment and Gametic Epigenetic Reprogramming.” Environmental and Molecular Mutagenesis, vol. 58, WILEY, 2017, pp. S28–S28.
Sweitzer, Maggie, et al. “ADHD, Smoking Withdrawal, and Resting State Functional Connectivity: Results of a fMRI Study With Methylphenidate Challenge.” Neuropsychopharmacology, vol. 41, NATURE PUBLISHING GROUP, 2016, pp. S614–15.
Kollins, Scott, et al. “Initial Response to Intranasal Nicotine Young Adults With and Without Attention Deficit Hyperactivity Disorder.” Neuropsychopharmacology, vol. 41, 2016, pp. S452–53.
Kollins, Scott H., et al. “6.41 A SIX-MONTH OPEN-LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF PRC-063 IN ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER.” Journal of the American Academy of Child &Amp; Adolescent Psychiatry, vol. 55, no. 10, Elsevier BV, 2016, pp. S217–S217. Crossref, doi:10.1016/j.jaac.2016.09.361. Full Text
Kollins, Scott H., et al. “6.42 A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY MEASURING THE EFFICACY AND SAFETY OF A NOVEL, EXTENDED-RELEASE FORMULATION OF METHYLPHENIDATE (PRC-063) IN ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER.” Journal of the American Academy of Child &Amp; Adolescent Psychiatry, vol. 55, no. 10, Elsevier BV, 2016, pp. S217–18. Crossref, doi:10.1016/j.jaac.2016.09.362. Full Text